Dr. Sotiris G. Mitropanopoulos, MD
Neurology (Neurology Physician)
5777 E Mayo Blvd
Phoenix, AZ 85054
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Arizona College of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 329
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: University of Arizona College of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
AZ license 58709 · FL license ME142433 · FL license L7880 · MN license 60522 · WI license 67673 -
Clinical Neurophysiology Physician
FL license ME142433 -
Epilepsy Physician
FL license ME142433
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Hospital Phoenix, AZ
Medical groups
- Mayo Clinic Arizona (1,626 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 329
- Services billed
- 945
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 124 | 69 |
| New patient office or other outpatient visit, 60-74 minutes | 115 | 115 |
| Established patient office or other outpatient visit, 40-54 minutes | 72 | 68 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 35 | 22 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 21 or more minutes | 29 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 22 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Phoenix, AZ | 50 |
| Duloxetine Hcl Other prescribers in Phoenix, AZ | 46 |
| Pregabalin Other prescribers in Phoenix, AZ | 35 |
| Clonazepam Other prescribers in Phoenix, AZ | 20 |
| Levetiracetam Er (levetiracetam) Other prescribers in Phoenix, AZ | 18 |
| Lamotrigine Other prescribers in Phoenix, AZ | 17 |
| Lorazepam Other prescribers in Phoenix, AZ | 16 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Phoenix, AZ | 15 |
| Verapamil Er (verapamil hcl) Other prescribers in Phoenix, AZ | 15 |
| Oxcarbazepine Other prescribers in Phoenix, AZ | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $750 in research payments for these studies, mostly to the institutions running them.
- Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
Immedica Pharma US, Inc. · Terminated · NCT05604170
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.